Why the study?
Does low molecular weight heparin improve outcomes compared to warfarin in patients with cancer-related venous thromboembolism?
Does low molecular weight heparin improve outcomes compared to warfarin in patients with cancer-related venous thromboembolism?
This review highlights that low molecular weight heparin is superior to warfarin for managing cancer-related venous thromboembolism and emphasizes the need for appropriate thromboprophylaxis in hospitalized cancer patients.
Answers are grounded in this paper and cite their sources.
Supports LMWH preference in cancer VTE; leaves open optimal integration of DOACs and prophylaxis duration.
The association between venous thromboembolism and cancer has been recognized for over 140 years. This article reviews current prevention, diagnosis and treatment of cancer-related venous thromboembolism, and highlights emerging anticoagulants and the possible anticancer effects of anticoagulants such as low molecular weight heparins.
No takes yet. Share an insight, caveat, or question.
Noble et al. (2009) conducted a review in Venous thromboembolism in cancer. Low molecular weight heparin vs. Warfarin was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: